Tag: Durvalumab
AstraZeneca Pharma India receives CDSCO approval for Durvalumab
The drug is targeted at the patients with Unresectable Hepatocellular Carcinoma (uHCC)
AstraZeneca’s Durvalumab receives CDSCO approval in India
The product is used for treatment of patients with locally advanced or metastatic Biliary Tract Cancer
AstraZeneca receives marketing permission for Durvalumab (ImfinziTM) in India
Durvalumab is the only immunotherapy approved for patients with unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) and was granted US FDA ‘breakthrough therapy’ designation on July 31, 2017.....................